Long Shortz with Neurizon Therapeutics: Last patient completes treatment in OLE study

Tylah Tully speaks with Neurizon MD Michael Thurn after the final patient completes treatment in the NUZ-001 OLE study.

Tylah Tully speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn following a major milestone in the company’s NUZ-001 program, as the final patient in its Open-Label Extension study completes treatment.

Neurizon's also one of eight companies accepted into the Healey ALS Platform Trial out of over fifty applicants, presenting NUZ with the prospect of accelerated approval from the US FDA, potentially enabling it to launch NUZ-001 worldwide in the near future.

Watch the video to hear about the company's plans.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.